You are here

Complex differential spectral interferometry

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL079781-02
Agency Tracking Number: HL079781
Amount: $749,904.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Timeline
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SOUTHWEST SCIENCES, INC. 1570 PACHECO ST, STE E-11
SANTA FE, NM 87505
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANIEL KANE
 (505) 984-1322
 DJKANE@SWSCIENCES.COM
Business Contact
 ALAN STANTON
Phone: (505) 984-1322
Email: ASTANTON@SWSCIENCES.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Summary. Atherosclerosis is indicated by the American Heart Association as a primary factor in three fourths of deaths resulting from cardiovascular disease. It is now recognized that many coronary events and strokes are caused by atherosclerotic plaques that rupture - vulnerable plaques. It is important that the cardiologist be able to assess the risk of plaque rupture when diagnosing and treating persons with atherosclerosis. Currently available imaging tools (angioscopy, MRI, intravascular ultrasound) do not provide the high spatial resolution needed for this application. We propose to develop a rapid, high resolution optical imaging method for imaging of venous and arterial structures that will aid in the diagnosis of atherosclerosis, specifically in identifying vulnerable plaques. The new technique, which we call complex differential spectral interferometry (CDSI), will be an important improvement to optical coherence tomography (OCT). It will provide video-rate cross-sectional imaging and will have higher dynamic range than standard time domain OCT. It will be fully compatible with fiber optics allowing incorporation into endoscopes, catheters and similar devices for in vivo applications. In Phase I, we achieved a breakthrough in the development of CDSI (also known as complex Fourier domain OCT). The newly developed version resolves the problem of the complex conjugate ambiguity (one of the main drawbacks of Fourier domain OCT) in an elegant and exceptionally efficient way, which provides a two-fold increase of the maximum imaging depth. In Phase II, the new technique will be used with a novel detector, recently designed and built at Southwest Sciences. The proposed technology takes full advantage of parallel detection inherent in CDSI allowing the greater dynamic range and sensitivity of Fourier domain OCT to be realized. Relevance. Cardiovascular disease affects over 61 million Americans and is the leading cause of death in the US. The major risk is associated with atherosclerotic plaques that rupture - vulnerable plaques, - which are difficult to diagnose with currently available methods. The proposed technology will aid in the diagnosis of vulnerable atherosclerotic plaques, thus providing important information for the cardiologist making risk assessments and choosing the best course of treatment, ultimately, saving lives.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government